Holen Sie sich die Stockscreener-App
12.74
1.51%
0.19
Schlusskurs vom Vortag:
$12.55
Offen:
$12.51
24-Stunden-Volumen:
979.08K
Relative Volume:
0.81
Marktkapitalisierung:
$1.93B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-4.4702
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
+1.92%
1M Leistung:
-17.49%
6M Leistung:
-53.54%
1J Leistung:
-24.26%
1-Tages-Spanne:
$12.41
$12.87
1-Wochen-Bereich:
$12.02
$13.63
52-Wochen-Spanne:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8548
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
12.74 | 1.93B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
(DNLI) Technical Data - news.stocktradersdaily.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Denali Therapeutics stock hits 52-week low at $12.05 By Investing.com - Investing.com Canada
Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Zacks Investment Research
Denali Therapeutics set to advance groundbreaking treatments for neurological diseases - MSN
Denali Therapeutics advances Hunter syndrome treatment BLA By Investing.com - Investing.com South Africa
What Happened To Denali Therapeutics Stock Wednesday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Sector Update: Health Care Stocks Advance in Late Afternoon Trading - TradingView
Sector Update: Health Care - MarketScreener
Denali Therapeutics begins marketing application for genetic disorder drug, shares rise - TradingView
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier - BioSpace
Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up - MarketScreener
How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals
Denali Therapeutics advances Hunter syndrome treatment BLA - Investing.com India
Denali Therapeutics Announces Initiation of BLA Filing for - GlobeNewswire
Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome - MarketScreener
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire
Breakthrough: Denali's Hunter Syndrome Drug Enters Final FDA Approval Stage - Stock Titan
Trend Tracker for (DNLI) - news.stocktradersdaily.com
Denali Therapeutics stock hits 52-week low at $13.95 By Investing.com - Investing.com South Africa
Denali Therapeutics stock hits 52-week low at $13.95 - Investing.com Australia
Exponential Growth Expected for Blood Brain Barrier Market With - openPR.com
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha
Why You Shouldn't Bet Against Denali (DNLI) Stock - Barchart
(DNLI) On The My Stocks Page - news.stocktradersdaily.com
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Denali halts extension of DNL343 arm in HEALEY ALS trial - ALS News Today
Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World
Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World
Why Denali Therapeutics Shares Are Tumbling - TipRanks
Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World
How the (DNLI) price action is used to our Advantage - Stock Traders Daily
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Denali's ALS programme suffers another setback - pharmaphorum
What is B. Riley’s Forecast for DNLI FY2029 Earnings? - Defense World
Morgan Stanley initiates Denali stock with Overweight rating - Investing.com
B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - Defense World
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback - Benzinga India
Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G - TipRanks
Denali Therapeutics Discontinues DNL343 ALS Trial - TipRanks
DNLI stock touches 52-week low at $14.55 amid market challenges - Investing.com Australia
B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating - MarketScreener
Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade - Defense World
DNLI stock touches 52-week low at $14.55 amid market challenges By Investing.com - Investing.com South Africa
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Yahoo Finance
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Denali Therapeutics Inc-Aktie (DNLI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
175,673 |
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '25 |
Sale |
20.22 |
12,255 |
247,796 |
247,215 |
| Schuth Alexander O. | COFO and Secretary |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
244,308 |
| Watts Ryan J. | President and CEO |
Jan 06 '25 |
Sale |
20.22 |
29,266 |
591,759 |
260,721 |
| Watts Ryan J. | President and CEO |
Jan 07 '25 |
Sale |
20.81 |
7,650 |
159,196 |
253,071 |
| Krognes Steve E. | Director |
Jan 07 '25 |
Sale |
20.81 |
3,339 |
69,485 |
25,757 |
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):